ES2535723T3 - Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 - Google Patents

Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 Download PDF

Info

Publication number
ES2535723T3
ES2535723T3 ES10732183.8T ES10732183T ES2535723T3 ES 2535723 T3 ES2535723 T3 ES 2535723T3 ES 10732183 T ES10732183 T ES 10732183T ES 2535723 T3 ES2535723 T3 ES 2535723T3
Authority
ES
Spain
Prior art keywords
sample
preferable embodiment
cancer
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10732183.8T
Other languages
English (en)
Spanish (es)
Inventor
Michael Bates
Jennifer W. Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Application granted granted Critical
Publication of ES2535723T3 publication Critical patent/ES2535723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10732183.8T 2009-01-15 2010-01-15 Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 Active ES2535723T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US176630P 2000-01-19
US14502909P 2009-01-15 2009-01-15
US145029P 2009-01-15
US17663009P 2009-05-08 2009-05-08
US18796209P 2009-06-17 2009-06-17
US187962P 2009-06-17
PCT/US2010/021281 WO2010083470A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Publications (1)

Publication Number Publication Date
ES2535723T3 true ES2535723T3 (es) 2015-05-14

Family

ID=42340114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10732183.8T Active ES2535723T3 (es) 2009-01-15 2010-01-15 Métodos de determinación de la respuesta del paciente mediante la medición de Her-3

Country Status (12)

Country Link
US (4) US8349574B2 (https=)
EP (1) EP2387711B1 (https=)
JP (1) JP5746051B2 (https=)
KR (1) KR20110120891A (https=)
CN (1) CN102460152B (https=)
AU (1) AU2010204583A1 (https=)
BR (1) BRPI1007321A2 (https=)
CA (1) CA2749846C (https=)
ES (1) ES2535723T3 (https=)
IL (1) IL214072A (https=)
SG (2) SG172983A1 (https=)
WO (1) WO2010083470A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
US8357277B2 (en) 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
US8470542B2 (en) * 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20120295259A1 (en) * 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
JP5718319B2 (ja) * 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
WO2011047087A2 (en) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Protein detection via nanoreporters
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR101992502B1 (ko) * 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105209881B (zh) 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
WO2014165855A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
JP6419796B2 (ja) * 2013-10-04 2018-11-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
EP3325649B1 (en) 2015-07-17 2024-01-03 Nanostring Technologies, Inc. Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
WO2017015099A1 (en) 2015-07-17 2017-01-26 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN108780089B (zh) * 2016-03-15 2020-09-08 美国控股实验室公司 评估细胞间的蛋白质相互作用的方法
AU2018246872C1 (en) 2017-03-31 2023-05-18 Merus B.V. ErbB-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbB-3, for treatment of an individual with an erbB-2, erbB-2/erbB-3 positive tumour
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
KR20250161650A (ko) 2018-02-12 2025-11-17 브루커 스페이셜 바이올로지, 인크. 유전자 및 단백질 발현을 검출하는 생체 분자 프로브 및 방법

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117165B1 (https=) 1973-12-27 1976-05-31
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU636110B2 (en) 1988-06-08 1993-04-22 Nichols Institute Diagnostics Assays utilizing sensitizer-induced production of detectable signal
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0484027B1 (en) 1990-11-02 1996-12-18 Zeneca Limited Polysubstituted phthalocyanines
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE162892T1 (de) 1992-07-31 1998-02-15 Behringwerke Ag Photoaktivierbare chemiluminizierende matrices
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
SE9601676D0 (sv) 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US20040248150A1 (en) 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6682887B1 (en) 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US20030092012A1 (en) 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7833698B2 (en) * 2000-01-12 2010-11-16 Ventana Medical Systems, Inc. Method for determining the response to cancer therapy
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
WO2001084157A2 (en) 2000-05-04 2001-11-08 Dade Behring Marburg Gmbh Compositions for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
US6630296B2 (en) 2000-08-08 2003-10-07 Aclara Biosciences, Inc. Multiplexed enzymatic assays
WO2002017437A1 (en) 2000-08-19 2002-02-28 Kim Sung Cheol Communication line separator
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
WO2002094998A2 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Analyzing phosphorylated proteins
PL373962A1 (en) 2001-05-21 2005-09-19 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2002097112A2 (en) 2001-05-26 2002-12-05 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
WO2003006947A2 (en) 2001-07-09 2003-01-23 Aclara Biosciences, Inc. Cell-screening assay and composition
WO2003055439A2 (en) 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
AU2002319613A1 (en) 2001-07-19 2003-03-03 Signet Laboratories, Inc. Human tissue specific drug screening procedure
GB2378245A (en) 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
CA2456732C (en) 2001-08-07 2012-10-30 Galephar M/F Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20050043820A1 (en) 2001-10-12 2005-02-24 James Browning Biomaterial comprising microfeatures
WO2003033741A1 (en) 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
JP2005509859A (ja) 2001-11-09 2005-04-14 アクララ バイオサイエンシーズ， インコーポレイテッド タグ標識された微粒子組成物および方法
AU2002363725A1 (en) 2001-11-09 2003-05-26 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
EP1497455A4 (en) 2001-11-09 2005-12-28 Aclara Biosciences Inc DETECTION OF NUCLEIC ACID SEQUENCES BY CLEAVAGE AND SEPARATION OF MARKED STRUCTURES
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ES2352180T3 (es) * 2002-02-26 2011-02-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anticuerpo monoclonal de anti-tenascina humana.
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2003085374A2 (en) 2002-04-02 2003-10-16 Aclara Biosciences, Inc. Multiplexed assays using electrophoretically separated molecular tags
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20090111127A1 (en) 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040175765A1 (en) 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2493671A1 (en) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
AU2003291249A1 (en) 2002-12-18 2004-07-29 Aclara Biosciences, Inc. Multiplexed immunohistochemical assays using molecular tags
EP1599492A4 (en) 2003-01-17 2008-09-24 Virologic Inc RECIPIENTS DORPHANIZATION BY USING MARKED MOLECULAR LIBRARIES
CA2521077A1 (en) 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
WO2005019470A2 (en) 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
WO2005017493A2 (en) 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
US20050106571A1 (en) 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
EP1681983A4 (en) 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
DE602005023529D1 (de) 2004-11-03 2010-10-21 Iris Molecular Diagnostics Inc Homogener nachweis von analyten
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006068640A1 (en) * 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
RU2007133660A (ru) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
WO2007041502A2 (en) * 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
WO2007115571A2 (en) 2006-04-07 2007-10-18 Enkam Pharmaceuticals A/S Erbb receptor-derived peptide fragments
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
US8357277B2 (en) 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (zh) 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
CA2711843C (en) 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172984A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3

Also Published As

Publication number Publication date
KR20110120891A (ko) 2011-11-04
SG10201408392PA (en) 2015-01-29
EP2387711B1 (en) 2015-04-22
CA2749846A1 (en) 2010-07-22
CA2749846C (en) 2018-08-07
US20100210034A1 (en) 2010-08-19
CN102460152A (zh) 2012-05-16
SG172983A1 (en) 2011-08-29
JP2012515226A (ja) 2012-07-05
EP2387711A4 (en) 2012-07-18
IL214072A (en) 2016-08-31
US10775382B2 (en) 2020-09-15
WO2010083470A1 (en) 2010-07-22
BRPI1007321A2 (en) 2018-07-10
JP5746051B2 (ja) 2015-07-08
CN102460152B (zh) 2014-11-26
AU2010204583A2 (en) 2011-09-01
US20130071859A1 (en) 2013-03-21
AU2010204583A1 (en) 2011-08-25
US9110066B2 (en) 2015-08-18
US9766242B2 (en) 2017-09-19
US8349574B2 (en) 2013-01-08
US20180164319A1 (en) 2018-06-14
US20160061839A1 (en) 2016-03-03
IL214072A0 (en) 2011-08-31
EP2387711A1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
ES2535723T3 (es) Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
US10273308B2 (en) Methods of producing antibodies specific for p95
Singer et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
ES2526519T3 (es) Métodos de determinación de la respuesta del paciente por medición de la expresión HER-2
US10416162B2 (en) Her2 diagnostic methods
ES2701929T3 (es) Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
ES2285469T3 (es) Utilizacion de la proteina celular transportadora de acido retinoico de tipo ii (crabp ii) como marcador del cancer de mama.
Wang et al. Expression Characteristics of Clinically Relevant Antibody–Drug Conjugate Targets in Gestational Trophoblastic Neoplasia
US20080299589A1 (en) Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers